PTC Therapeutics, Inc. (PTCT)

NASDAQ

$76.25

+$0.61 (0.81%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$75.45$77.17

Open $76.00

52 Week Range

$35.95$87.50

Previous Close $75.64

Market Cap6.12B

Volume998.09K

Avg Volume1.56M

P/E (TTM)7.96

EPS (TTM)$9.58

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for PTC Therapeutics, Inc.

DEC12025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: PRNewsWire•14 days ago

WARREN, N.J., Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricte...

DEC12025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Source: GlobeNewsWire•15 days ago

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment o...

NOV242025

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

Source: PRNewsWire•21 days ago

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE: IPG)...

NOV202025

PTC Therapeutics to Host R&D Day

Source: PRNewsWire•26 days ago

Event to take place on Dec. 2, 2025 in New York City WARREN, N.J. , Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m....

NOV42025

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Source: PRNewsWire•41 days ago

– Initiated US and EU launch of Sephience™ (sepiapterin) – – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 reve...

OCT312025

PTC Therapeutics to Participate at Upcoming Investor Conferences

Source: PRNewsWire•46 days ago

WARREN, N.J. , Oct. 31, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: UBS Global Healthcare Conference 2025 Tuesday, Nov. 11 at 3:30 p.m....

OCT272025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: PRNewsWire•49 days ago

WARREN, N.J. , Oct. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 1,990 restrict...

OCT212025

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

Source: PRNewsWire•56 days ago

WARREN, N.J. , Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business...

OCT12025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: PRNewsWire•75 days ago

WARREN, N.J. , Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept....